Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism Transcript
Source: SeekingAlpha
2025-11-18 19:28:46 ET
Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism November 18, 2025 3:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism Transcript
Nxera Pharma Co Ltd Ord
NASDAQ: SOLTF
SOLTF Trading
0.0% G/L:
$7.314 Last:
100 Volume:
$7.314 Open:
SOLTF Latest News
June 01, 2026 07:30:00 pm
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea
May 26, 2026 06:22:27 am
Nxera's President & CEO to Participate in a 'Fireside Chat' at the Jefferies New York Healthcare Conference 2026
May 11, 2026 02:34:51 am
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
May 08, 2026 06:26:31 am
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology
